PARAMUS, N.J., Jan. 14, 2013 /PRNewswire/ -- Proteonomix,
Inc. (the "Company") (SYMBOL: PROT), a biotechnology company (the
"Company") focused on developing therapeutics based upon the use of
human cells and their derivatives, announced today that it has
extended the record date for shareholders on that date to receive
shares of the new BVI (British Virgin
Islands) corporation that will receive sublicenses and
assignments of the UMK-121 and Proteoderm technologies.
Due to confusion among shareholders and the short time frame
previously set, especially for shareholders holding in street name,
we are responding to shareholder concerns and extending the
deadline to the close of business on Friday,
January 18, 2013. The licensing and assignments of the
technologies will also be delayed until that date.
About Proteonomix, Inc.
Proteonomix is a biotechnology company focused on developing
therapeutics based upon the use of human cells and their
derivatives. The Proteonomix family of companies presently includes
Proteoderm, StromaCel, PRTMI and THOR Biopharma. Proteoderm is a
wholly owned subsidiary that has developed an anti-aging line of
skin care products. StromaCel develops therapeutic modalities for
the treatment of cardiovascular disease and for treatment of
patients who have suffered post-myocardial infarction. Proteonomix
Regenerative Translational Medicine Institute, Inc. (PRTMI) intends
to focus on the translation of promising research in stem cell
biology and cellular therapy to clinical applications of
regenerative medicine. Additional information is available at
www.proteonomix.com and www.proteoderm.com.
Forward-looking statements:
Certain statements contained herein are "forward-looking
statements" (as defined in the Private Securities Litigation Reform
Act of 1995). Proteonomix, Inc. cautions that statements made in
this press release constitute forward-looking statements and makes
no guarantee of future performance. Actual results or developments
may differ materially from projections. Forward-looking statements
are based on estimates and opinions of management at the time
statements are made.
SOURCE Proteonomix, Inc.
